A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
<h4>Background</h4>Up to 80% of patients dying from prostate carcinoma have developed bone metastases that are incurable. Castration is commonly used to treat prostate cancer. Although the disease initially responds to androgen blockade strategies, it often becomes castration-resistant (...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/eafaa204b5594d94961e809b03c8f723 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:eafaa204b5594d94961e809b03c8f723 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:eafaa204b5594d94961e809b03c8f7232021-11-18T08:54:31ZA new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.1932-620310.1371/journal.pone.0075092https://doaj.org/article/eafaa204b5594d94961e809b03c8f7232013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24069383/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Up to 80% of patients dying from prostate carcinoma have developed bone metastases that are incurable. Castration is commonly used to treat prostate cancer. Although the disease initially responds to androgen blockade strategies, it often becomes castration-resistant (CRPC for Castration Resistant Prostate Cancer). Most of the murine models of mixed lesions derived from prostate cancer cells are androgen sensitive. Thus, we established a new model of CRPC (androgen receptor (AR) negative) that causes mixed lesions in bone.<h4>Methods</h4>PC3 and its derived new cell clone PC3c cells were directly injected into the tibiae of SCID male mice. Tumor growth was analyzed by radiography and histology. Direct effects of conditioned medium of both cell lines were tested on osteoclasts, osteoblasts and osteocytes.<h4>Results</h4>We found that PC3c cells induced mixed lesions 10 weeks after intratibial injection. In vitro, PC3c conditioned medium was able to stimulate tartrate resistant acid phosphatase (TRAP)-positive osteoclasts. Osteoprotegerin (OPG) and endothelin-1 (ET1) were highly expressed by PC3c while dikkopf-1 (DKK1) expression was decreased. Finally, PC3c highly expressed bone associated markers osteopontin (OPN), Runx2, alkaline phosphatase (ALP), bone sialoprotein (BSP) and produced mineralized matrix in vitro in osteogenic conditions.<h4>Conclusions</h4>We have established a new CRPC cell line as a useful system for modeling human metastatic prostate cancer which presents the mixed phenotype of bone metastases that is commonly observed in prostate cancer patients with advanced disease. This model will help to understand androgen-independent mechanisms involved in the progression of prostate cancer in bone and provides a preclinical model for testing the effects of new treatments for bone metastases.Anaïs FradetHélène SorelBaptiste DepalleClaire Marie SerreDelphine FarlayAndrei TurtoiAkeila BellahceneHélène FolletVincent CastronovoPhilippe ClézardinEdith BonnelyePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 9, p e75092 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Anaïs Fradet Hélène Sorel Baptiste Depalle Claire Marie Serre Delphine Farlay Andrei Turtoi Akeila Bellahcene Hélène Follet Vincent Castronovo Philippe Clézardin Edith Bonnelye A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. |
| description |
<h4>Background</h4>Up to 80% of patients dying from prostate carcinoma have developed bone metastases that are incurable. Castration is commonly used to treat prostate cancer. Although the disease initially responds to androgen blockade strategies, it often becomes castration-resistant (CRPC for Castration Resistant Prostate Cancer). Most of the murine models of mixed lesions derived from prostate cancer cells are androgen sensitive. Thus, we established a new model of CRPC (androgen receptor (AR) negative) that causes mixed lesions in bone.<h4>Methods</h4>PC3 and its derived new cell clone PC3c cells were directly injected into the tibiae of SCID male mice. Tumor growth was analyzed by radiography and histology. Direct effects of conditioned medium of both cell lines were tested on osteoclasts, osteoblasts and osteocytes.<h4>Results</h4>We found that PC3c cells induced mixed lesions 10 weeks after intratibial injection. In vitro, PC3c conditioned medium was able to stimulate tartrate resistant acid phosphatase (TRAP)-positive osteoclasts. Osteoprotegerin (OPG) and endothelin-1 (ET1) were highly expressed by PC3c while dikkopf-1 (DKK1) expression was decreased. Finally, PC3c highly expressed bone associated markers osteopontin (OPN), Runx2, alkaline phosphatase (ALP), bone sialoprotein (BSP) and produced mineralized matrix in vitro in osteogenic conditions.<h4>Conclusions</h4>We have established a new CRPC cell line as a useful system for modeling human metastatic prostate cancer which presents the mixed phenotype of bone metastases that is commonly observed in prostate cancer patients with advanced disease. This model will help to understand androgen-independent mechanisms involved in the progression of prostate cancer in bone and provides a preclinical model for testing the effects of new treatments for bone metastases. |
| format |
article |
| author |
Anaïs Fradet Hélène Sorel Baptiste Depalle Claire Marie Serre Delphine Farlay Andrei Turtoi Akeila Bellahcene Hélène Follet Vincent Castronovo Philippe Clézardin Edith Bonnelye |
| author_facet |
Anaïs Fradet Hélène Sorel Baptiste Depalle Claire Marie Serre Delphine Farlay Andrei Turtoi Akeila Bellahcene Hélène Follet Vincent Castronovo Philippe Clézardin Edith Bonnelye |
| author_sort |
Anaïs Fradet |
| title |
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. |
| title_short |
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. |
| title_full |
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. |
| title_fullStr |
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. |
| title_full_unstemmed |
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. |
| title_sort |
new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/eafaa204b5594d94961e809b03c8f723 |
| work_keys_str_mv |
AT anaisfradet anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT helenesorel anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT baptistedepalle anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT clairemarieserre anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT delphinefarlay anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT andreiturtoi anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT akeilabellahcene anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT helenefollet anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT vincentcastronovo anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT philippeclezardin anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT edithbonnelye anewmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT anaisfradet newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT helenesorel newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT baptistedepalle newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT clairemarieserre newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT delphinefarlay newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT andreiturtoi newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT akeilabellahcene newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT helenefollet newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT vincentcastronovo newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT philippeclezardin newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer AT edithbonnelye newmurinemodelofosteoblasticosteolyticlesionsfromhumanandrogenresistantprostatecancer |
| _version_ |
1718421175168663552 |